TABLE 3.

Survival of piglets orally challenged with 1010 CFU of STEC 86-24 followed by i.p. administration of PBS (placebo) or 5C12 antibody at 48 h after bacterial challenge

TreatmentDose (mg/kg)Total no. of pigletsNo. (%) of surviving pigletsaDays of survival after infection (mean ± SD)bSerum IgG1(κ) concn (μg/ml)c
5C12688 (100)16.9 ± 7.4
Placebo070 (0)4.6 (±1.9)0
5C12344 (100)11.4 ± 1.2
Placebo030 (0)4.6 (±0.6)0
5C120.7565 (83)3.02.0 ± 1.2
Placebo0503.4 (±0.5)0
5C120.454 (80)4.00.7 ± 0.5
Placebo0703.4 (±0.5)
5C120.251 (20)4.0 (±1.4)0.6 ± 0.1
Placebo0603.5 (±0.8)
5C120.174 (57)7.0 (±3.4)0.18 ± 0.04
Placebo0804.2 (±1.7)
5C120.0541 (25)7.0 (±3.4)0.07 ± 0.03
Placebo0804.2 (±1.7)
  • a Piglets that did not survive either died overnight or were euthanized due to severe illness.

  • b Data for surviving piglets in the 5C12 group who were euthanized at the end of the experimental period (7 to 14 days) are included. Data for the piglets who were euthanized or died in the 5C12 group at another time are not included.

  • c Results reflect the concentration in serum of the human IgG1(κ) isotype, which is the isotype of 5C12. Values are means ± standard deviations.